| PFG |
Report |
Operating EPS (Q2 2026) |
BEAT |
pred ~$2.40 vs. cons $2.343 |
MEDIUM |
| PFG |
Report |
SBD Incurred Loss Ratio (Q2 2026) |
BEAT |
pred ~59.5% vs. cons 60.45% |
MEDIUM |
| PFG |
Report |
IM Net Cash Flows (Q2 2026) |
BEAT |
pred ~-$3.5B vs. cons -$5.49B |
MEDIUM |
| PFG |
Guide |
FY 2026 Operating EPS (FY 2026) |
BETTER |
guide ~$9.50-9.55 vs. cons $9.44 |
MEDIUM |
| PFG |
Guide |
FY 2026 IM Net Cash Flows (FY 2026) |
BETTER |
guide better than cons -$10.87B; normalization narrative |
MEDIUM |
| PFG |
Guide |
FY 2026 SBD Loss Ratio (FY 2026) |
UNCHANGED |
reaffirm low-end language; no change to range |
HIGH |
| PFG |
Return |
Day-1 residual (stock − beta × S&P 500) |
+3.0% |
— |
MEDIUM |
| PFG |
Return |
5-day cumulative residual |
+5.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH - H2 estimate revisions chase the implied out-period math upward; short covering sustains the bid |
MEDIUM |